非那雄胺与前列腺癌发病率及病理分级的meta分析.pdfVIP

堡壁迭篁堡董 非那雄胺与前列腺癌发病率及病理分级的Meta分析 冀 楠① 李晋军①。 漆咏梅①② 摘要：应用Meta分析法对有关非那雄胺与前列腺癌发病率及病理分级关系的研究进行综舍评价。符合标准的8篇文献进行 Meta分析。计算比值比(()R)、95％可信区间(95 那雄胺治疗前列腺增生能降低前列腺癌的发病风险。也能使发生的前列腺癌的病理级别增高。 关键词：非那雄胺。前列腺癌。发病率，病理分级。Meta分析 中图分类号：R737．25文献标识码：A 文章编号：1002—0772(2011)03—0029—03 onthe betweenFinasterideandIncidenceand ofProstateCancerJJ Meta—analysisRelationship PathologyGrading Nan。LI Scienceand J Yong—mei．Wuhan Technology。Wuhan430065，China in-jun，Qj Universityof alltherelatedstudiestOevaluatethe betweenfinasterideandincidenceand Abstract：Analyzing relationship pathologygrad— of cancermeansof thereferencesconsistentwithinclusion ingprostateby Meta—analysis．Toanalyze theoddsratioand95％confidence wereidentifiedandfoundno interval．Eightpublications 0．51)．Theriskof cancerinBPH couldbedecreasedinfinasteridetreatmentthancontrol prostate patients group．The in ORforthe was biaswerenotfoundthestud— pooled study0．68195％CI：0．65～0．71，Z=17．16，P一0．00)．Publication test the of of y，byusingEgger’Smethod(P=0．21)．Individingpathologygrading cancer，themalignantdegree prostate cancer than couldbeincreasedinBPH of finasteridecasecontr01．The 0Rforthe prostate patientsusing summary study was